These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34930386)

  • 1. The prognostic factor for recurrence in advanced-stage high-grade serous ovarian cancer after complete clinical remission: a nested case-control study.
    Wang Q; Zheng Y; Wang P; Zhang J; Liu H; Li Q; Yin R; Bian C; Peng H; Peng Z
    J Ovarian Res; 2021 Dec; 14(1):179. PubMed ID: 34930386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High grade, advanced, serous ovarian cancer with low serum CA125 levels.
    Asali A; Haj-Yehia N; Zehavi T; Perry T; Beiner M; Fishman A; Kadan Y
    J Obstet Gynaecol; 2021 Oct; 41(7):1107-1111. PubMed ID: 33427544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Has serum CA 125 assay at the time of relapse a prognostic relevance for patients with recurrent ovarian carcinoma after primary cytoreduction and platinum- and paclitaxel-based chemotherapy?
    Gadducci A; Notarnicola M; Menichetti A; Lanfredini N; Fanucchi A; Cosio S
    Eur J Gynaecol Oncol; 2016; 37(2):182-8. PubMed ID: 27172742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
    Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
    J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of elevated pretreatment serum levels of CEA and CA-125 in epithelial ovarian cancer.
    Lin YH; Wu CH; Fu HC; Chen YJ; Chen YY; Ou YC; Lin H
    Cancer Biomark; 2020; 28(3):285-292. PubMed ID: 32390605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated Preoperative CA125 or CA19-9 in Borderline Ovarian Tumors: Could It Be Suggestive of Advanced Stage or a Poor Prognosis?
    Song T; Lee DH; Jung YW; Yun BS; Seong SJ; Choi CH; Lee JW; Bae DS; Kim BG
    Gynecol Obstet Invest; 2018; 83(1):45-51. PubMed ID: 28571024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rising serum CA-125 levels within the normal range is strongly associated recurrence risk and survival of ovarian cancer.
    Piatek S; Panek G; Lewandowski Z; Bidzinski M; Piatek D; Kosinski P; Wielgos M
    J Ovarian Res; 2020 Sep; 13(1):102. PubMed ID: 32878632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of rising serum CA-125 levels within the normal range in patients with epithelial ovarian, primary peritoneal, and tubal cancers, who, after initial treatment, had a complete clinical response.
    Levy T; Weiser R; Boaz M; Shem EB; Golan A; Menczer J
    Int J Gynecol Cancer; 2012 Oct; 22(8):1344-8. PubMed ID: 22954785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer.
    Piatek S; Panek G; Lewandowski Z; Piatek D; Kosinski P; Bidzinski M
    Sci Rep; 2021 Sep; 11(1):18190. PubMed ID: 34521891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-Grade Serous Ovarian Cancer: Use of Machine Learning to Predict Abdominopelvic Recurrence on CT on the Basis of Serial Cancer Antigen 125 Levels.
    Shinagare AB; Balthazar P; Ip IK; Lacson R; Liu J; Ramaiya N; Khorasani R
    J Am Coll Radiol; 2018 Aug; 15(8):1133-1138. PubMed ID: 29789232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Ovarian Cancer Relapse score: a prognostic algorithm to predict relapse following treatment for advanced ovarian cancer.
    Rizzuto I; Stavraka C; Chatterjee J; Borley J; Hopkins TG; Gabra H; Ghaem-Maghami S; Huson L; Blagden SP
    Int J Gynecol Cancer; 2015 Mar; 25(3):416-22. PubMed ID: 25647256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
    Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
    Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction effects of serum CA125 decrease ratio during different cycles in relapsed ovarian cancer.
    Wang J; Liu Y; Li J; Lu X
    J Obstet Gynaecol Res; 2019 May; 45(5):1006-1011. PubMed ID: 30687999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [CA 125 regression after two cycles of neoadjuvant chemotherapy as prognostic factor in patients with advanced ovarian cancer and primary peritoneal serous cancer who underwent interval surgical cytoreduction].
    Gasowska-Bodnar A; Bodnar L; Wcisło GB; Jerzak MM; Szczylik C; Baranowski W
    Ginekol Pol; 2008 Feb; 79(2):108-14. PubMed ID: 18510089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer.
    Sun J; Cui XW; Li YS; Wang SY; Yin Q; Wang XN; Gu L
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7276-7283. PubMed ID: 32706065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study.
    van Altena AM; Kolwijck E; Spanjer MJ; Hendriks JC; Massuger LF; de Hullu JA
    Gynecol Oncol; 2010 Nov; 119(2):265-9. PubMed ID: 20797777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative CA-125 Value as a Predictive Factor for Postoperative Outcome in First Relapse of Platinum-sensitive Serous Ovarian Cancer.
    Parashkevova A; Sehouli J; Richter R; Dimitrova D; Braicu EI; Muallem MZ
    Anticancer Res; 2018 Aug; 38(8):4865-4870. PubMed ID: 30061261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An increase of serum CA-125 to two times of nadir level strongly predicts the image-identified relapse of serous ovarian cancer.
    Du K; Li Q; Huang J; Chan DW; Li J; Chang X; Wang H; Tang J; Yang Q
    Sci Rep; 2024 Jul; 14(1):14986. PubMed ID: 38951620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of serum HE4 as a prognostic marker in carcinoma of the ovary.
    Lakshmanan M; Kumar V; Chaturvedi A; Misra S; Gupta S; Akhtar N; Rajan S; Jain K; Garg S
    Indian J Cancer; 2019; 56(3):216-221. PubMed ID: 31389384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial.
    Rustin GJ; van der Burg ME; Griffin CL; Guthrie D; Lamont A; Jayson GC; Kristensen G; Mediola C; Coens C; Qian W; Parmar MK; Swart AM; ;
    Lancet; 2010 Oct; 376(9747):1155-63. PubMed ID: 20888993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.